Literature DB >> 9044836

CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP.

M Ahmad1, S M Srinivasula, L Wang, R V Talanian, G Litwack, T Fernandes-Alnemri, E S Alnemri.   

Abstract

FADD/MORT1 is a death domain (DD)-containing adaptor/signaling molecule that interacts with the intracellular DD of FAS/APO-I (CD95) and tumor necrosis factor receptor 1 and the prodomain of caspase-8 (Mch5/MACH/FLICE). FADD engagement of caspase-8 presumably activates this caspase and leads to apoptosis. Another DD-containing adaptor/signaling molecule, CRADD, was identified and was shown to induce apoptosis. CRADD has a dual-domain structure similar to that of FADD. It has an NH2-terminal caspase homology domain that interacts with caspase-2 and a COOH-terminal DD that interacts with RIP. CRADD is constitutively expressed in many tissues and thus could play a role in regulating apoptosis in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9044836

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

1.  Mechanisms of apoptosis.

Authors:  J C Reed
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

2.  Regulation of CRADD-caspase 2 cascade by histone deacetylase 1 in gastric cancer.

Authors:  Qi Shen; Wanfen Tang; Jie Sun; Lifeng Feng; Hongchuan Jin; Xian Wang
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

3.  Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.

Authors:  Andreas Zettl; Thomas Rüdiger; Maria-Anette Konrad; Andreas Chott; Ingrid Simonitsch-Klupp; Ruth Sonnen; Hans Konrad Müller-Hermelink; German Ott
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 4.  The protein structures that shape caspase activity, specificity, activation and inhibition.

Authors:  Pablo Fuentes-Prior; Guy S Salvesen
Journal:  Biochem J       Date:  2004-12-01       Impact factor: 3.857

5.  Cytokine suppression of protease activation in wild-type p53-dependent and p53-independent apoptosis.

Authors:  J Lotem; L Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

6.  Requirements for proteolysis during apoptosis.

Authors:  D L Vaux; S Wilhelm; G Häcker
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

7.  Two pathways of apoptosis are simultaneously induced in the embryonal brains of neural cell-specific HIF-1alpha-deficient mice.

Authors:  Masaki Ueno; Shuhei Tomita; Masaaki Ueki; Yasuyuki Iwanaga; Cheng-Long Huang; Masayuki Onodera; Nobuhiro Maekawa; Frank J Gonzalez; Haruhiko Sakamoto
Journal:  Histochem Cell Biol       Date:  2005-11-15       Impact factor: 4.304

Review 8.  Apoptosis: a new pharmacodynamic endpoint.

Authors:  J L Au; N Panchal; D Li; Y Gan
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

Review 9.  Immunopathology of apoptosis--introduction and overview.

Authors:  D L Vaux
Journal:  Springer Semin Immunopathol       Date:  1998

10.  Genome-wide association study suggests four variants influencing outcomes with ranibizumab therapy in exudative age-related macular degeneration.

Authors:  Masato Akiyama; Atsushi Takahashi; Yukihide Momozawa; Satoshi Arakawa; Fuyuki Miya; Tatsuhiko Tsunoda; Kyota Ashikawa; Yuji Oshima; Miho Yasuda; Shigeo Yoshida; Hiroshi Enaida; Xue Tan; Yasuo Yanagi; Tsutomu Yasukawa; Yuichiro Ogura; Yoshimi Nagai; Kanji Takahashi; Kimihiko Fujisawa; Maiko Inoue; Akira Arakawa; Koji Tanaka; Mitsuko Yuzawa; Kazuaki Kadonosono; Koh-Hei Sonoda; Tatsuro Ishibashi; Michiaki Kubo
Journal:  J Hum Genet       Date:  2018-07-27       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.